Avilar Therapeutics Presents New In Vivo Non-Human Primate Data for ASGPR-Targeting Chimeras (ATACs) at the Keystone Symposium on Targeted Protein Degradation

WALTHAM, MA, USA I November 07, 2022 IAvilar Therapeutics, a biopharmaceutical company focused on extracellular protein degradation, today presented new preclinical proof-of-concept data demonstrating the degradation of extracellular proteins using its asialoglycoprotein receptor (ASGPR) targeting chimera (ATAC) platform at the Keystone Symposium on Targeted Protein Degradation being held in Vancouver, British Columbia. The company presented in vivo proof-of-concept data in non-human primates showing robust and dose-dependent degradation of a circulating extracellular protein by a monovalent ATAC degrader.

“We are excited to present new data in non-human primates demonstrating strong in vivo proof of concept for ATAC-mediated extracellular protein degradation,” said Effie Tozzo, CSO of Avilar Therapeutics. “These compelling data further validate the potential of our ATAC platform and have also directly informed the design and development of our pipeline ATACs targeting serious diseases.”

Highlights of the results presented at the Keystone Symposium include:

  • Avilar’s proprietary small molecule high-affinity ASGPR ligands enabled the synthesis of novel bivalent and monovalent ATAC degraders of Immunoglobulin G (IgG), an abundant and long half-life extracellular protein.
  • In non-human primate repeat-dose studies, both monovalent and bivalent ATACs showed dose-dependent plasma exposure and robust dose-dependent degradation (>80%) of IgG when dosed intravenously.
  • A monovalent ATAC degrader dosed subcutaneously in a non-human primate repeat-dose study demonstrated dose-dependent plasma exposure and equally robust IgG degradation activity as monovalent or bivalent ATACs dosed intravenously.
  • Avilar’s proprietary extracellular degradation modeling simulation technology, customized for ASGPR-mediated uptake and degradation, predicted the dose, dosing regimen, and PK/PD profile of ATACs in vivo.

The poster is available on the Avilar website.

About Avilar Therapeutics

Avilar Therapeutics is a biopharmaceutical company pioneering the discovery and development of extracellular protein degraders, a new frontier in targeted protein degradation. Avilar develops ATACs (ASGPR Targeting Chimeras), a new class of protein degraders that shuttle disease-causing proteins from circulation to the endolysosome where the unwanted proteins are degraded. Avilar has built a proprietary ATAC platform that includes novel, high-affinity, small molecule ASGPR ligands and advanced modeling of the biophysics, pharmacokinetics, and pharmacodynamics of ATAC mediated endocytosis and degradation. The ATAC platform enables the modular design and synthesis of ATACs extendable across the extracellular proteome to a wide range of proteins involved in the pathogenesis of human diseases. Avilar is leveraging the ATAC platform to create a broad and diverse pipeline of first-in-class extracellular protein degraders. Avilar was founded and financed by RA Capital Management and based in Waltham, MA. For more information, please visit www.avilar-tx.com and follow us on Twitter @Avilar_Tx and on LinkedIn.

SOURCE: Avilar Therapeutics

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top